Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed a Share Transfer Agreement to acquire a 85.7143% stake in Hunan Tianjicaotang Pharmaceutical CO.,LTD. from Weng Xiaotao and Xiang Zhongyou for CNY 340 million.
November 15, 2022
Share
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) signed the share acquisition intent framework agreement acquire a 85.7143% stake in Hunan Tianjicaotang Pharmaceutical CO.,LTD. from Weng Xiaotao and Xiang Zhongyou for approximately CNY 340 million on November 16, 2022. Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed a Share Transfer Agreement to acquire a 85.7143% stake in Hunan Tianjicaotang Pharmaceutical CO.,LTD. from Weng Xiaotao and Xiang Zhongyou for CNY 340 million on December 20, 2022. Hunan Dajiaweikang Pharmaceutical will use use its own funds or self-raised funds to acquire 60 million shares in Hunan Tianjicaotang. Hunan Dajiaweikang Pharmaceutical Industryr board of directors on December 30, 2022, and reviewed and approved the transaction. On December 30, 2022, signed the "Supplement to the Share Transfer Agreement between Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. and a Weng Xiaotao and Xiang Zhongyou in Yuelu District, Changsha with Weng Xiaotao and Xiang Zhongyou, shareholders of Tianji Caotang Pharmaceutical Co., Ltd. Total 15 million non-restricted target shares held by the transferor (accounting for 21.4286% of the total shares of the Hunan Tianjicaotang Pharmaceutical, including 11.25 million shares of Weng Xiaotao and 3.75 million shares of Xiang Zhongyou). Currently Hunan Tianjicaotang Pharmaceutical CO.,LTD has completed the delisting and the first share delivery, and simultaneously changed the register of shareholders.
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed a Share Transfer Agreement to acquire a 85.7143% stake in Hunan Tianjicaotang Pharmaceutical CO.,LTD. from Weng Xiaotao and Xiang Zhongyou for CNY 340 million.